William Blair Keeps Their Hold Rating on Audentes Therapeutics (BOLD)

By Austin Angelo

William Blair analyst Raju Prasad maintained a Hold rating on Audentes Therapeutics (BOLDResearch Report) yesterday. The company’s shares closed yesterday at $37.03.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 13.6% and a 49.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Logicbio Therapeutics Inc.

Audentes Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $46.50.

See today’s analyst top recommended stocks >>

Based on Audentes Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $49.39 million. In comparison, last year the company had a GAAP net loss of $31.37 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.